Is switching treatments from PDE5 inhibitors to riociguat an option in patients with PAH?

Prof. Dr. med. Marius Hoeper
Department of Pneumology, Medical School Hanover

In this short presentation Prof. Hoeper explains whether riociguat is an option in PAH treatment for patients with an insufficient response to PDE-5 inhibitors.